Uso de N-acetilcisteína en pacientes que desarrollaron hepatitis por medicamentos antituberculosos: revisión sistemática.
Saved in:
| Title: | Uso de N-acetilcisteína en pacientes que desarrollaron hepatitis por medicamentos antituberculosos: revisión sistemática. |
|---|---|
| Alternate Title: | Use of N-acetylcysteine in patients with hepatitis by antitubercular agents: systematic review. |
| Authors: | JULIÁN ARISTIZÁBAL-HERNÁNDEZ, JOSÉ1 josej.aristizabal@upb.edu.co, MARÍA BRAVO-ANDRADE, ANA2 anabravo3@hotmail.com, HENAO-VILLADA, ALEJANDRO2 alejandro99henao@gmail.com, MAZO-CAÑOLA, ANDREA2, HERNANDO DONADO-GÓMEZ, JORGE3 jorge.donado@upb.edu.co |
| Source: | Salud Uninorte. sep-dic2023, Vol. 39 Issue 3, p1017-1033. 17p. |
| Subjects: | ANTITUBERCULAR agents, CLINICAL trials, CINAHL database, DRUG side effects, PLACEBOS |
| Abstract (English): | The aim of this systematic review was to estimate the effectiveness of N-Acetylcysteine in the treatment of hepatotoxicity induced by antitubercular agents, we included randomized clinical trials, there was no language nor publication status restriction, published until December 2021. The searched databases were CENTRAL, CINAHL, LILACS, MEDLINE, Pubmed, Scielo, Scopus y Web of Science; out of 33 articles found, one of them met the inclusion criteria and had low bias risk. The time to biochemical resolution was 7,5 days (IQR 5,5-11) in the treatment arm, and 8 (IQR 5-13) in the placebo arm. Time of hospital stay was 9 days (IQR 6-15) in the treatment arm, and 18 (IQR 10-25) in the placebo arm. Mortality (14 %) didn't differ between groups. Further clinical trials may be needed to determine the therapeutic role of N-acetylcysteine in patients with drug-induced liver injury caused by antituberculous agents. [ABSTRACT FROM AUTHOR] |
| Abstract (Spanish): | El objetivo de esta revisión sistemática fue estimar la efectividad de la N-acetilcisteína en el tratamiento de hepatotoxicidad por antituberculosos; se incluyeron ensayos clínicos controlados aleatorizados, sin restricciones de idioma ni estado de publicación; se tuvieron en cuenta estudios publicados hasta diciembre de 2022. Búsqueda en bases de datos bibliográficas: CENTRAL, CINAHL, LILACS, MEDLINE, Pubmed, Scielo, Scopus y Web of Science; de 33 artículos encontrados, uno cumplió los criterios de inclusión con bajo riesgo de sesgos. El tiempo a mejoría bioquímica del grupo intervención fue 7,5 días (RIQ 5,5-11) y en el grupo placebo 8 (RIQ 5-13). El tiempo de estancia hospitalaria en el grupo intervención fue 9 días (RIQ 6-15) y en el grupo placebo 18 (RIQ 10-25). La mortalidad no difirió entre grupos y fue 14 %. No es posible concluir sobre el efecto terapéutico de la N-acetilcisteína en pacientes con DILI por antituberculosos, lo cual justifica realizar ensayos clínicos. [ABSTRACT FROM AUTHOR] |
| Copyright of Salud Uninorte is the property of Fundacion Universidad del Norte and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) | |
| Database: | MedicLatina |
| FullText | Links: – Type: pdflink Text: Availability: 0 |
|---|---|
| Header | DbId: lth DbLabel: MedicLatina An: 174367676 AccessLevel: 6 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Uso de N-acetilcisteína en pacientes que desarrollaron hepatitis por medicamentos antituberculosos: revisión sistemática. – Name: TitleAlt Label: Alternate Title Group: TiAlt Data: Use of N-acetylcysteine in patients with hepatitis by antitubercular agents: systematic review. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AR" term="%22JULIÁN+ARISTIZÁBAL-HERNÁNDEZ%2C+JOSÉ%22">JULIÁN ARISTIZÁBAL-HERNÁNDEZ, JOSÉ</searchLink><relatesTo>1</relatesTo><i> josej.aristizabal@upb.edu.co</i><br /><searchLink fieldCode="AR" term="%22MARÍA+BRAVO-ANDRADE%2C+ANA%22">MARÍA BRAVO-ANDRADE, ANA</searchLink><relatesTo>2</relatesTo><i> anabravo3@hotmail.com</i><br /><searchLink fieldCode="AR" term="%22HENAO-VILLADA%2C+ALEJANDRO%22">HENAO-VILLADA, ALEJANDRO</searchLink><relatesTo>2</relatesTo><i> alejandro99henao@gmail.com</i><br /><searchLink fieldCode="AR" term="%22MAZO-CAÑOLA%2C+ANDREA%22">MAZO-CAÑOLA, ANDREA</searchLink><relatesTo>2</relatesTo><br /><searchLink fieldCode="AR" term="%22HERNANDO+DONADO-GÓMEZ%2C+JORGE%22">HERNANDO DONADO-GÓMEZ, JORGE</searchLink><relatesTo>3</relatesTo><i> jorge.donado@upb.edu.co</i> – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22Salud+Uninorte%22">Salud Uninorte</searchLink>. sep-dic2023, Vol. 39 Issue 3, p1017-1033. 17p. – Name: Subject Label: Subjects Group: Su Data: <searchLink fieldCode="DE" term="%22ANTITUBERCULAR+agents%22">ANTITUBERCULAR agents</searchLink><br /><searchLink fieldCode="DE" term="%22CLINICAL+trials%22">CLINICAL trials</searchLink><br /><searchLink fieldCode="DE" term="%22CINAHL+database%22">CINAHL database</searchLink><br /><searchLink fieldCode="DE" term="%22DRUG+side+effects%22">DRUG side effects</searchLink><br /><searchLink fieldCode="DE" term="%22PLACEBOS%22">PLACEBOS</searchLink> – Name: Abstract Label: Abstract (English) Group: Ab Data: The aim of this systematic review was to estimate the effectiveness of N-Acetylcysteine in the treatment of hepatotoxicity induced by antitubercular agents, we included randomized clinical trials, there was no language nor publication status restriction, published until December 2021. The searched databases were CENTRAL, CINAHL, LILACS, MEDLINE, Pubmed, Scielo, Scopus y Web of Science; out of 33 articles found, one of them met the inclusion criteria and had low bias risk. The time to biochemical resolution was 7,5 days (IQR 5,5-11) in the treatment arm, and 8 (IQR 5-13) in the placebo arm. Time of hospital stay was 9 days (IQR 6-15) in the treatment arm, and 18 (IQR 10-25) in the placebo arm. Mortality (14 %) didn't differ between groups. Further clinical trials may be needed to determine the therapeutic role of N-acetylcysteine in patients with drug-induced liver injury caused by antituberculous agents. [ABSTRACT FROM AUTHOR] – Name: Abstract Label: Abstract (Spanish) Group: Ab Data: El objetivo de esta revisión sistemática fue estimar la efectividad de la N-acetilcisteína en el tratamiento de hepatotoxicidad por antituberculosos; se incluyeron ensayos clínicos controlados aleatorizados, sin restricciones de idioma ni estado de publicación; se tuvieron en cuenta estudios publicados hasta diciembre de 2022. Búsqueda en bases de datos bibliográficas: CENTRAL, CINAHL, LILACS, MEDLINE, Pubmed, Scielo, Scopus y Web of Science; de 33 artículos encontrados, uno cumplió los criterios de inclusión con bajo riesgo de sesgos. El tiempo a mejoría bioquímica del grupo intervención fue 7,5 días (RIQ 5,5-11) y en el grupo placebo 8 (RIQ 5-13). El tiempo de estancia hospitalaria en el grupo intervención fue 9 días (RIQ 6-15) y en el grupo placebo 18 (RIQ 10-25). La mortalidad no difirió entre grupos y fue 14 %. No es posible concluir sobre el efecto terapéutico de la N-acetilcisteína en pacientes con DILI por antituberculosos, lo cual justifica realizar ensayos clínicos. [ABSTRACT FROM AUTHOR] – Name: AbstractSuppliedCopyright Label: Group: Ab Data: <i>Copyright of Salud Uninorte is the property of Fundacion Universidad del Norte and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract.</i> (Copyright applies to all Abstracts.) |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=lth&AN=174367676 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.14482/sun.39.03.005.258 Languages: – Code: spa Text: Spanish PhysicalDescription: Pagination: PageCount: 17 StartPage: 1017 Subjects: – SubjectFull: ANTITUBERCULAR agents Type: general – SubjectFull: CLINICAL trials Type: general – SubjectFull: CINAHL database Type: general – SubjectFull: DRUG side effects Type: general – SubjectFull: PLACEBOS Type: general Titles: – TitleFull: Uso de N-acetilcisteína en pacientes que desarrollaron hepatitis por medicamentos antituberculosos: revisión sistemática. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: JULIÁN ARISTIZÁBAL-HERNÁNDEZ, JOSÉ – PersonEntity: Name: NameFull: MARÍA BRAVO-ANDRADE, ANA – PersonEntity: Name: NameFull: HENAO-VILLADA, ALEJANDRO – PersonEntity: Name: NameFull: MAZO-CAÑOLA, ANDREA – PersonEntity: Name: NameFull: HERNANDO DONADO-GÓMEZ, JORGE IsPartOfRelationships: – BibEntity: Dates: – D: 01 M: 09 Text: sep-dic2023 Type: published Y: 2023 Identifiers: – Type: issn-print Value: 01205552 Numbering: – Type: volume Value: 39 – Type: issue Value: 3 Titles: – TitleFull: Salud Uninorte Type: main |
| ResultId | 1 |
